The FOXFIRE and FOXFIRE Global Studies

FOXFIRE and FOXFIRE Global are randomized controlled clinical studies comparing SIR-Spheres® Y-90 resin microspheres in combination with standard-of care chemotherapy versus chemotherapy alone in first-line treatment of metastatic colorectal cancer (mCRC).

Both studies recruited chemotherapy-naïve patients with non-resectable liver metastases from primary colorectal cancer, with or without limited extra-hepatic disease.

FOXFIRE study design:

FOXFIRE Global study design:

The FOXFIRE study recruited >360 patients from the UK and the FOXFIRE Global study recruited >200 patients globally. The study designs of FOXFIRE, FOXFIRE Global and SIRFLOX are similar and the primary endpoint of Overall Survival will be assessed in a combined analysis of all three studies. The analysis will include data from >1,100 patients and is expected to be released in 2017.

Secondary endpoints of the FOXFIRE and FOXFIRE Global studies include Progression-Free Survival (PFS), PFS in the Liver, Safety and Toxicity, Healthcare Costs/Health Economics, Health-Related Quality of Life, Response Rate, Liver Resection Rate and the interval to and proportion of patients receiving second-line treatment.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.